Trial Profile

Stress Urinary Incontinence Study to Assess Safety and Efficacy of Muvon's Muscle Precursor Cell Therapy

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 27 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Autologous-muscle-precursor-cells-MUVON-Therapeutics (Primary)
Indications Urinary-Stress-Incontinence
Focus Therapeutic Use
Acronyms SUISSE MPC 2

Most Recent Events

03 Dec 2025 According to a MUVON Therapeutics media release, company plans to submit the full data set for publication in a peer-reviewed journal and to present the results at leading upcoming international medical conferences.
03 Dec 2025 Primary endpoint has been met (Change of SUI episode frequency) , according to a MUVON Therapeutics media release
03 Dec 2025 Results presented in a MUVON Therapeutics media release

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com